Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In

 Latest News

Pharmerit research on adverse events related to corticosteroid use in uveitis patients has been selected for a free paper session at IOIS 2015.
Patricia Benton, a senior finance executive, has joined Pharmerit International as Chief Financial Officer, managing partners Jennifer Stephens and Lex Tergau announced today.
In this report we evaluated the published studies and argue that acute hyperglycaemia is worth investigating in relation to the real-life implications.
This study reassess the costs and effects of photoselective vaporization of the prostate (PVP) versus transurethral resection of the prostate (TURP) on the basis of most recent data.
​Coronary heart disease (CHD) is a major public health concern; it is the leading cause of mortality worldwide, accounting for more than 7 million deaths each year.
The study presents a cost-effective treatment option for patients with chronic genotype 1 HCV infection
​A systematic literature review was conducted to provide an overview of published literature in the last 10-years.
The model allows patients to move through a treatment sequence with treatment response measured via ACR criteria
ISPOR and Value in Health, journal for research that advance the field of pharmacogenomics and outcomes research, endorse Pharmerit’s academic research on reimbursement in Scotland.
Type 2 diabetes mellitus is estimated to account for 7–12% of the UK National Health Service expenditure. Economic analysis is critical to ensuring that limited resources are used effectively.
Contact Feel free to contact us if you have any questions